Clinical trial
An Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects
NCT04819581 is registered in ClinicalTrials.gov with Scilex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects
- Lead sponsor
- Scilex Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 3, 2019
- Completion date
- August 27, 2019
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy